This will play a video - MiniMed 670G insulin pump on blue background




By purchasing the MiniMed™ 670G system today, your patients will automatically be eligible for the Next Tech Pathway program, which helps them access our next technology when it’s released. The last day they can place an order and be enrolled is December 1, 2020.

Download a program flyer today to discuss with your patients.

A female clinician helps a male patient learn how to operate their new Medtronic insulin pump.
When you buy the MiniMed 670G system, your patient will be automatically enrolled in the Next Tech Pathway program. When new technology is available, we'll notify your patient it's time to upgrade and when they're ready, we'll send them a new device.


The MiniMed™ 670G system offers SmartGuard™ technology, the only technology that mimics some of the functions of a healthy pancreas by providing two levels of automated insulin delivery.

MiniMed 670G, Guardian Sensor 3 continuous glucose monitor, and glucose meter on white background


SmartGuard™ Auto Mode:

  • Automatically adjusts basal (background) insulin every five minutes based on CGM readings†1
  • Helps keep sugar levels in target range for fewer lows and highs, day and night†1

See how Auto Mode works


Request information for your patients and a representative will follow up shortly.


The Next Tech Pathway program is available to any of your patients who purchase a MiniMed™ 670G system and meet one of the following requirements:

  • New to Medtronic insulin pump therapy
  • Upgrading from an out-of-warranty pump

This program is not available to customers on a rental program such as those including but not limited to any federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DOD”), or TRICARE.


* Indicates a required field.

By clicking Submit, I confirm that I have read and agree to the Authorization and permit Medtronic to use my contact information for the purposes described in the authorization. Read More.

Together, we are transforming diabetes care so people with diabetes can enjoy greater freedom and better health.


See below for questions your patients may ask regarding the Next Tech Pathway program.

Expand All

How much will it cost to purchase the MiniMed™ 670G system?

The easiest way to get in touch with Medtronic is to fill out their form at and a therapy specialist will reach out to discuss options and estimated costs.  

How long will it take to buy the MiniMed™ 670G system?

When can I upgrade to a new pump through the Next Tech Pathway program?

Are there costs to upgrade through the Next Tech Pathway program?

Does my warranty change if I upgrade through the Next Tech Pathway program?

I purchased my pump before this program launched. Can I still $0 upgrade?

How many options will I have for a Next Tech Pathway upgrade?

How is this different from the Pathway program?

Why can’t I be in the program if I buy MiniMed™ 630G system?

I’m excluded from the program because of my insurance. Will I be able to upgrade later?


Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary. The MiniMed™ 670G System can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Based on clinical study data in pivotal trial. Individual results may vary.

Based on sensor glucose.




dQ&A Patient Panel. [Q4 2016 Summary Report]. dQ&A 2017.

Terms and Conditions

The Next Tech Pathway program (the “Program”) allows eligible, enrolled participants whose MiniMed 670G system order is shipped starting on 11/7/19 to be included. The last day to place an order is 12/1/20. This Program allows for an upgrade to our next MiniMed system at $0. Eligibility dates subject to change.

To be eligible for the Program, participants must purchase a MiniMed™ 670G system and meet one of the following requirements:

  • New to Medtronic insulin pump therapy
  • Upgrade from an out-of-warranty pump

This program is not available to customers on a rental program such as those enrolled in federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DoD”) or TRICARE.

To upgrade through the Program, all participants must agree and are subject to these terms and conditions:

  • Return of old MiniMed 670G insulin pump and transmitter is required. If the old pump and transmitter is not returned within 90 days, you will be charged $3,200.
  • Warranty period does not reset when you receive the new technology. The warranty period of an upgraded insulin pump and transmitter will remain the same as the warranty date of the initial pump and transmitter purchased.
  • MiniMed pumps have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider.
  • Upon first commercial shipping of a new MiniMed system, it may take up to 90 days for Medtronic to contact you with the option to upgrade. Once you place your order, it may take up to 90 days to ship the new product. The Program does not guarantee prioritization of your order.
  • An upgrade through the Program can only be redeemed once during your warranty period for the next available technology and customers’ order must ship no later than 4/1/21. The Program cannot be redeemed if less than six (6) months remains on your pump warranty.
  • The Program for the future upgrade applies to one (1) in-warranty insulin pump and one (1) in-warranty transmitter. CGM sensors and consumables are not included, however, these Medtronic products will remain compatible.
  • If transmitter is out of warranty, customer will need to purchase a new transmitter.
  • Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
  • A valid prescription will be required to purchase a new pump. All participants should consult their healthcare provider for all therapy related decisions.
  • Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.


The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult and the appropriate user guide at

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Ascensia Diabetes Care Logo

Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.